دورية أكاديمية
BIM deletion polymorphisms in hispanic patients with non-small cell lung cancer carriers of EGFR mutations
| العنوان: | BIM deletion polymorphisms in hispanic patients with non-small cell lung cancer carriers of EGFR mutations |
|---|---|
| المؤلفون: | Cardona-Mendoza, Andrés Felipe, Rojas Puentes, Leonardo, Wills, Beatriz, Arrieta, Oscar, Carranza Isaza, Hernán, Vargas Báez, Carlos Alberto, Otero, Jorge, Corrales-Rodriguez, Luis, Martín, Claudio, Reguart, Noemi, Archila, Pilar, Rodríguez Ariza, July Katherine, Cuello, Mauricio, Ortíz, Carlos, Franco, Sandra, Rolfo, Christian, Rosell, Rafael |
| المساهمون: | Cardona-Mendoza, Andrés Felipe 0000-0002-6697-5471, Carranza Isaza, Hernán 0000-0002-3593-7405, Vargas Báez, Carlos Alberto 0000-0002-6076-8260, Rojas Puentes, Leonardo 0000-0002-7865-5424, Rodríguez Ariza, July Katherine 0000-0003-1168-595X |
| بيانات النشر: | Impact Journals Oncotarget |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Neoplasias pulmonares, Proteína 11 similar a Bcl2, Genes erbB-1, BIM deletion, Non-small cell lung cancer, EGFR mutation, Survival |
| الوصف: | Background: Germline alterations in the proapoptotic protein Bcl-2-like 11 (BIM) can have a crucial role in diverse tumors. To determine the clinical utility of detecting BIM deletion polymorphisms (par4226 bp/ par363 bp) in EGFR positive non-small-cell lung cancer (NSCLC) we examined the outcomes of patients with and without BIM alterations. Results: BIM deletion was present in 14 patients (15.7%). There were no significant differences between patients with and without BIM-del in clinical characteristics or EGFR mutation type; however, those with BIM-del had a worse overall response rate (ORR) to erlotinib (42.9% vs. 73.3% in patients without BIM-del; p=0.024) as well as a significantly shorter progression-free survival (PFS) (10.8 BIM-del+ vs. 21.7 months for patients without BIM-del; p=0.029) and overall survival (OS) (15.5 BIM-del+ vs. 34.0 months for patients without BIM-del; p=0.035). Multivariate Cox regression analysis showed that BIM-del+ was an independent indicator of shorter PFS (HR 3.0; 95%CI 1.2-7.6; p=0.01) and OS (HR 3.4; 95%CI 1.4-8.3; p=0.006). Methods: We studied 89 NSCLC Hispanic patients with EGFR mutation who were treated with erlotinib between January 2009 and November 2014. BIM deletion polymorphisms (BIM-del) was analyzed by PCR in formalin-fixed paraffin-embedded (FFPE) tissues of tumor biopsies. We retrospectively analyzed clinical characteristics, response rate, toxicity, and outcomes among patients with and without BIM-del. Conclusions: The incidence of BIM-del found in Hispanic patients is similar to that previously described in Asia. This alteration is associated with a poor clinical response to erlotinib and represents an independent prognostic factor for patients who had NSCLC with an EGFR mutation. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1949-2553 |
| العلاقة: | Oncotarget, 1949-2553. Vol, 7, Nro, 42. 2016.; https://www.oncotarget.com/article/12112/textTest/; http://hdl.handle.net/20.500.12495/2374Test; https://doi.org/10.18632/oncotarget.12112Test; instname:Universidad El Bosque; reponame: Repositorio Institucional Universidad El Bosque; repourl:https://repositorio.unbosque.edu.coTest |
| DOI: | 10.18632/oncotarget.12112 |
| الإتاحة: | https://doi.org/20.500.12495/2374Test https://doi.org/10.18632/oncotarget.12112Test https://hdl.handle.net/20.500.12495/2374Test |
| حقوق: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ ; Acceso abierto ; info:eu-repo/semantics/openAccess ; http://purl.org/coar/access_right/c_abf60Test ; 2016 |
| رقم الانضمام: | edsbas.F50548CB |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 19492553 |
|---|---|
| DOI: | 10.18632/oncotarget.12112 |